Literature DB >> 10723832

Deaths in methadone maintenance treatment in New South Wales, Australia 1990-1995.

D Zador1, S Sunjic.   

Abstract

AIMS: To determine the number and causes of deaths in methadone maintenance treatment (MMT).
DESIGN: Cross-sectional survey.
SETTING: New South Wales (NSW), Australia. PARTICIPANTS: Two hundred and thirty-eight patients who died while registered in MMT from 1990 to 1995. MEASUREMENTS: Data on number and causes of death in MMT were obtained from data on file at the NSW Health Department, NSW Registry of Births, Deaths and Marriages, and NSW Department of Courts Administration.
FINDINGS: The most common cause of death was drug-related (44%), followed by medical illness (24%). Fifty deaths (21%) occurred in the first week of MMT, 88% of which were drug-related. In 92% of these drug-related deaths, there was evidence of polydrug use. In all, 42% of all drug-related deaths occurred during the first week of MMT. Nearly half the cases of drug-related death (46%) in the first week were noted by the medical practitioner at assessment to have a history of polydrug abuse or dependence. Four (9%) drug-related cases were prescribed doses of methadone in excess of the-then current national methadone clinical guidelines.
CONCLUSION: The first 7 days of MMT is a high-risk period. Inadequate clinical review of subjects' tolerance to methadone and/or subjects' use of other central nervous system (CNS) depressant drugs probably contributed to most of these cases' deaths during induction. The findings from this study reinforce the importance of a thorough drug and alcohol assessment of people seeking MMT, cautious prescribing of methadone, frequent clinical review of patients' tolerance to methadone during induction and education about the dangers of additional drug use during this period.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10723832     DOI: 10.1046/j.1360-0443.2000.951778.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  19 in total

Review 1.  Methadone tolerance testing in drug misusers.

Authors:  Adam Bakker; Cindy Fazey
Journal:  BMJ       Date:  2006-11-18

2.  A Possible Mechanistic Link Between the CYP2C19 Genotype, the Methadone Metabolite Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidene (EDDP), and Methadone-Induced Corrected QT Interval Prolongation in a Pilot Study.

Authors:  John F Carlquist; David E Moody; Stacey Knight; Eric G Johnson; Wenfang B Fang; John A Huntinghouse; Jeffrey S Rollo; Lynn R Webster; Jeffrey L Anderson
Journal:  Mol Diagn Ther       Date:  2015-04       Impact factor: 4.074

3.  Comparison of opiate-primary treatment seekers with and without alcohol use disorder.

Authors:  Bryan Hartzler; Dennis M Donovan; Zhen Huang
Journal:  J Subst Abuse Treat       Date:  2010-07-03

4.  Effect of TRV130 and methadone on fentanyl-vs.-food choice and somatic withdrawal signs in opioid-dependent and post-opioid-dependent rats.

Authors:  E Andrew Townsend; Bruce E Blough; David H Epstein; S Stevens Negus; Yavin Shaham; Matthew L Banks
Journal:  Neuropsychopharmacology       Date:  2022-07-29       Impact factor: 8.294

Review 5.  Methadone deaths: risk factors in pain and addicted populations.

Authors:  Vania Modesto-Lowe; Donna Brooks; Nancy Petry
Journal:  J Gen Intern Med       Date:  2010-01-20       Impact factor: 5.128

6.  Mechanism of autoinduction of methadone N-demethylation in human hepatocytes.

Authors:  Scott D Campbell; Amanda Crafford; Brian L Williamson; Evan D Kharasch
Journal:  Anesth Analg       Date:  2013-06-03       Impact factor: 5.108

Review 7.  Polydrug abuse: a review of opioid and benzodiazepine combination use.

Authors:  Jermaine D Jones; Shanthi Mogali; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2012-08-02       Impact factor: 4.492

8.  Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial.

Authors:  John D Roache; Martina Pavlicova; Aimee Campbell; Tse-Hwei Choo; Michelle Peavy; Andrea S Kermack; Edward V Nunes; John Rotrosen
Journal:  Alcohol Clin Exp Res       Date:  2021-11-23       Impact factor: 3.455

9.  Buprenorphine versus dihydrocodeine for opiate detoxification in primary care: a randomised controlled trial.

Authors:  Nat M J Wright; Laura Sheard; Charlotte N E Tompkins; Clive E Adams; Victoria L Allgar; Nicola S Oldham
Journal:  BMC Fam Pract       Date:  2007-01-08       Impact factor: 2.497

Review 10.  Burden and nutritional deficiencies in opiate addiction- systematic review article.

Authors:  Sepideh Nabipour; Mas Ayu Said; Mohd Hussain Habil
Journal:  Iran J Public Health       Date:  2014-08       Impact factor: 1.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.